Every article, presentation, spotlight, and news item we've tagged to Devices and Wearables.
Showing 1–24 of 32
WHOOP has secured $575 million in Series G funding at a $10.1 billion valuation, positioning itself as a continuous health monitoring platform that translates physiological data into actionable guidance. The funding reflects investor confidence that longevity platforms embedding real-time health tracking into daily life can shift healthcare from reactive to proactive intervention.
WHOOP has joined a $34.5 million Stanford-led research initiative to develop the first FDA-grade Intrinsic Capacity score, a predictive model designed to quantify functional healthspan and forecast major health outcomes up to 20 years in advance. The THRIVE coalition integrates continuous wearable physiological data with clinical biomarkers and functional assessments to measure resilience and detect early shifts toward vulnerability before disease manifests.
Sky Labs received UK regulatory approval for CART PLATFORM, a cuffless ring-based blood pressure monitor that integrates wearable hardware, mobile app, and cloud analytics. The authorization enables prescription distribution through UK pharmacies and hospitals, establishing clinical-grade continuous blood pressure monitoring as an accessible diagnostic tool.
Oura has developed a proprietary AI model specifically designed to contextualize women's health questions using personal biometric data from its wearable ring. The system integrates clinical evidence with continuous physiological signals to provide personalized guidance rather than generic web-based information, addressing a gap in how most AI tools handle women's hormonal and reproductive physiology.
Sky Labs has developed CART, a ring-worn wearable that enables continuous, non-invasive blood pressure monitoring in hospital settings without traditional cuffs. This technology extends real-time hemodynamic tracking from intensive care units to general wards, improving early detection of cardiovascular changes and reducing clinical workload.
NextSense has commercialized in-ear EEG earbuds that move beyond sleep tracking to real-time neural modulation, using closed-loop audio stimulation timed to reinforce slow-wave sleep. This represents a shift from passive measurement to active intervention in a domain central to longevity—though validation across heterogeneous populations and safety protocols remain open questions.
Continuous passive monitoring via consumer wearables can detect meaningful variability in cognitive and mood patterns over months, capturing environmental and physiological influences on brain function earlier than episodic clinical assessment. The strongest predictive signals—sleep quality, heart rate patterns, and environmental exposure—suggest brain health is fundamentally linked to systemic and environmental conditions rather than isolated neural function.
Clair Health has launched a non-invasive wearable that uses multimodal biosensors and AI to infer continuous hormonal patterns across the female lifespan, moving beyond episodic blood tests and calendar-based tracking. The device collects skin temperature, heart rate variability, sleep, and breathing data as proxies for endocrine state, positioning hormonal monitoring as a prevention tool rather than a fertility marker.
Sky Labs secured exclusive distribution rights with Otsuka Pharmaceutical to bring CART BP pro, a cuffless blood pressure monitor using photoplethysmography technology, to Japanese hospitals and clinics. The device enables continuous 24-hour blood pressure monitoring without traditional cuffs, addressing a market of 43 million hypertensive Japanese patients where many remain uncontrolled or undiagnosed.
Function's acquisition of Getlabs removes logistical friction from routine health testing by bringing blood draws directly to patients' homes and offices. This operational change addresses a fundamental barrier to consistent health monitoring—the primary prerequisite for sustained, data-driven health optimization.
Seveno Capital's investment in PointFit reflects a market shift toward direct biochemical monitoring via wearable patches that measure lactate and other sweat biomarkers in real time. Continuous metabolic substrate tracking—rather than behavioral proxies like step count—provides actionable insight into energy dynamics, recovery debt, and metabolic flexibility relevant to both performance optimization and early detection of metabolic decline.
Temple, a wearable startup backed by former Zomato CEO Deepinder Goyal, has raised $54 million to develop a temple-worn device that continuously monitors cerebral blood flow. The device represents a shift in performance monitoring from peripheral metrics like heart rate to direct measurement of brain perfusion during cognitive and physical demands.
Google's redesign of Fitbit into Google Health repositions wearables as a data platform rather than a subscription product, leveraging AI-powered coaching to interpret health signals for users. This shift threatens the business models of standalone wearable companies by commoditizing their core tracking functions within a larger software ecosystem.
Beacon Biosignals raised $97 million in Series B extension funding to advance at-home EEG technology and AI-driven neural analytics for diagnostic and clinical applications. The capital supports commercialization of FDA-cleared wearable technology that captures real-world brain activity data for precision medicine.
NeuroRPM's FDA-cleared wearable platform will continuously monitor motor symptoms in a 500-participant Parkinson's disease trial, using Apple Watch data to measure bradykinesia, tremor, and dyskinesia with algorithmic precision. This represents the first FDA-cleared AI device for real-world Parkinson's symptom tracking, enabling detection of treatment response at granularity not achievable through standard clinical assessments alone.
Wearable devices tracking activity rhythms reveal that irregular movement patterns correlate with systemic inflammation and accelerated biological aging. This connection between circadian disruption and aging rate offers a quantifiable marker for longevity risk that precedes clinical disease.
Epia Neuro has launched an implantable brain-computer interface designed to help stroke survivors translate neural intent into functional movement through assistive devices. The approach prioritizes practical restoration of independence in daily life rather than speculative enhancement, addressing a significant gap in post-stroke rehabilitation where functional disability persists across years or decades.
Luffu, a new app from Fitbit co-founders Park and Friedman, monitors collective family health by tracking changes in individual rhythms over time through integrated data from devices, medical records, and daily observations. The product addresses evidence that strong family relationships provide physiological protection comparable to major lifestyle interventions, integrating relational health into the longevity conversation.
Ōura is assembling a health AI infrastructure platform through strategic acquisitions—integrating wearable data, metabolic tracking, clinical records, and performance analytics into a unified system designed to convert fragmented health signals into actionable guidance. This shift from passive tracking to real-time, AI-driven interpretation represents a fundamental change in how consumer health data could be organized and applied to longevity optimization.
Well Health and AliveCor have integrated Canadian cardiologist review into the Kardia mobile ECG platform, enabling users to obtain physician-evaluated cardiac assessments within 24 hours. This addresses extended specialist wait times while maintaining clinical oversight of AI-detected arrhythmias and cardiac conditions.
WELL Health has integrated Canadian cardiologists into AliveCor's Kardia platform to provide physician-reviewed ECG interpretation within 24 hours, addressing documented gaps in cardiology access where wait times have risen 53% nationally. This partnership combines AI-powered arrhythmia detection with human clinical validation to expand remote cardiac monitoring capacity.
Sava Technologies has demonstrated a minimally invasive microsensor that continuously monitors glucose for 10 days with accuracy comparable to traditional continuous glucose monitors, while requiring a filament roughly 10 times shorter and causing substantially less tissue disruption. This advance addresses a critical adoption barrier in glucose monitoring, where discomfort and skin irritation have limited consistent use despite established clinical benefits.
Eight Sleep's Pod smart mattress uses continuous biometric monitoring during sleep—tracking heart rate, heart rate variability, and breathing patterns—to shift from reactive treatment to predictive intervention. The company's $1.5 billion valuation reflects a strategic thesis that sleep represents both a high-frequency measurement window and an actionable intervention point for longevity and early disease detection.
SpectraCell's Baseline Nexus bundles four diagnostic tests—micronutrient status, lipoprotein particle profiling, telomere length, and MTHFR genotyping—into a single assessment designed to identify subclinical dysfunction before it progresses to clinical disease. The package reframes preventive diagnostics by measuring intracellular nutrient utilization and biological aging markers alongside conventional cardiovascular risk factors, enabling earlier intervention at the stage where metabolic and inflammatory processes are still modifiable.
